^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    nivatrotamab (GD2xCD3)

    i
    Other names: humanized anti-GD2 x anti-CD3 bispecific antibody, GD2xCD3, Hu3F8-BsAb, Humanized 3F8 Bispecific Antibody
    Associations

    News

    Trials
    Company:
    Memorial Sloan-Kettering Cancer Center, Y-mAbs Therap
    Drug class:
    CD3 agonist, GD2 ganglioside inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers (clinicaltrials.gov)
    P1/2, N=11, Terminated, Y-mAbs Therapeutics | N=30 --> 11 | Trial completion date: Feb 2022 --> Oct 2021 | Recruiting --> Terminated | Trial primary completion date: Feb 2022 --> Oct 2021; study terminated due to business priorities
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    nivatrotamab (GD2xCD3)